Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 22:3:971295.
doi: 10.3389/fpain.2022.971295. eCollection 2022.

Cancer cachexia: Pathophysiology and association with cancer-related pain

Affiliations
Review

Cancer cachexia: Pathophysiology and association with cancer-related pain

Michelle L Law. Front Pain Res (Lausanne). .

Abstract

Cachexia is a syndrome of unintentional body weight loss and muscle wasting occurring in 30% of all cancer patients. Patients with cancers most commonly leading to brain metastases have a risk for cachexia development between 20 and 80%. Cachexia causes severe weakness and fatigue and negatively impacts quality and length of life. The negative energy balance in cachectic patients is most often caused by a combination of increased energy expenditure and decreased energy intake. Basal metabolic rate may be elevated due to tumor secreted factors and a systemic inflammatory response leading to inefficiency in energy production pathways and increased energy demand by the tumor and host tissues. A growing body of research explores physiological and molecular mechanisms of metabolic dysregulation in cachexia. However, decreased energy intake and physical functioning also remain important contributors to cachexia pathogenesis. Pain associated with metastatic malignancy is significantly associated with inflammation, thus making inflammation a common link between cancer pain and cachexia. Pain may also influence appetite and food intake and exacerbate fatigue and functional decline, potentially contributing to cachexia severity. Cancer pain and cachexia often occur simultaneously; however, causal relationships remain to be established. Appropriate assessment and treatment of pain in advanced cancer patients may positively impact nutrition status and physical functioning, slowing the progression of cachexia and improving quality and length of life for patients.

Keywords: anorexia; cachexia; cancer; fatigue; inflammation; muscle atrophy; nutrition impact symptoms; pain.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Factors contributing to decreased energy intake and increased energy expenditure, leading to a net negative energy balance and weight loss in cancer cachexia. Negative energy balance in the presence of inflammation and related insulin resistance and oxidative stress favors loss of skeletal muscle mass via downregulation of protein synthesis and upregulation of protein degradation. UPS, ubiquitin-proteasome system, ALS, autophagy lysosome system.
Figure 2
Figure 2
Inflammation is a common link between cancer-related pain and cachexia. Other mediating factors commonly occurring with both pain and cachexia include decreased physical functioning, increased fatigue, impaired food intake, and decreased mental health.

References

    1. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. (2018) 4:17105. 10.1038/nrdp.2017.105 - DOI - PubMed
    1. Anker MS, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A, et al. . Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J Cachexia Sarcopenia Muscle. (2019) 10:22–34. 10.1002/jcsm.12402 - DOI - PMC - PubMed
    1. Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol. (2018) 149:27–42. 10.1016/B978-0-12-811161-1.00002-5 - DOI - PubMed
    1. Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, et al. . Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. (2016) 5:607–16. 10.1002/cam4.621 - DOI - PMC - PubMed
    1. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, et al. . Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. (2004) 90:1905–11. 10.1038/sj.bjc.6601781 - DOI - PMC - PubMed

LinkOut - more resources